JP6113277B2 - 酸素欠乏および気圧低下を原因とする高山病肺型の治療のための医薬組成物 - Google Patents

酸素欠乏および気圧低下を原因とする高山病肺型の治療のための医薬組成物 Download PDF

Info

Publication number
JP6113277B2
JP6113277B2 JP2015518983A JP2015518983A JP6113277B2 JP 6113277 B2 JP6113277 B2 JP 6113277B2 JP 2015518983 A JP2015518983 A JP 2015518983A JP 2015518983 A JP2015518983 A JP 2015518983A JP 6113277 B2 JP6113277 B2 JP 6113277B2
Authority
JP
Japan
Prior art keywords
peptide
seq
amino acid
medicament according
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015518983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526399A (ja
Inventor
ベルンハルト・フィッシャー
ルドルフ・ルカス
ヘンドリク・フィッシャー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apeptico Forschung und Entwicklung GmbH
Original Assignee
Apeptico Forschung und Entwicklung GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6113277(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apeptico Forschung und Entwicklung GmbH filed Critical Apeptico Forschung und Entwicklung GmbH
Publication of JP2015526399A publication Critical patent/JP2015526399A/ja
Application granted granted Critical
Publication of JP6113277B2 publication Critical patent/JP6113277B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2015518983A 2012-06-28 2013-06-19 酸素欠乏および気圧低下を原因とする高山病肺型の治療のための医薬組成物 Active JP6113277B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12173983.3A EP2679239A1 (de) 2012-06-28 2012-06-28 Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
EP12173983.3 2012-06-28
PCT/EP2013/062777 WO2014001177A1 (de) 2012-06-28 2013-06-19 Pharmazeutische zusammensetzung zur behandlung der durch sauerstoffarmut und verringerten luftdruck vermittelten pulmonalen form der höhenkrankheit

Publications (2)

Publication Number Publication Date
JP2015526399A JP2015526399A (ja) 2015-09-10
JP6113277B2 true JP6113277B2 (ja) 2017-04-12

Family

ID=48672620

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015518983A Active JP6113277B2 (ja) 2012-06-28 2013-06-19 酸素欠乏および気圧低下を原因とする高山病肺型の治療のための医薬組成物

Country Status (14)

Country Link
US (2) US9802985B2 (OSRAM)
EP (2) EP2679239A1 (OSRAM)
JP (1) JP6113277B2 (OSRAM)
KR (1) KR102010793B1 (OSRAM)
CN (1) CN104427993B (OSRAM)
AP (1) AP2014008162A0 (OSRAM)
AU (1) AU2013283563B2 (OSRAM)
CA (1) CA2875749C (OSRAM)
EA (1) EA030384B1 (OSRAM)
ES (1) ES2602197T3 (OSRAM)
IN (1) IN2015DN00585A (OSRAM)
MX (1) MX354302B (OSRAM)
PE (1) PE20150198A1 (OSRAM)
WO (1) WO2014001177A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015132294A1 (en) * 2014-03-04 2015-09-11 Apeptico Forschung Und Entwicklung Gmbh Attenuation of intrapulmonary inflammation
JP6397984B2 (ja) * 2014-03-18 2018-09-26 アペプティコ・フォルシュング・ウント・エントヴィックルング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＡｐｅｐｔｉｃｏ Ｆｏｒｓｃｈｕｎｇ Ｕｎｄ Ｅｎｔｗｉｃｋｌｕｎｇ Ｇｍｂｈ 乾燥粉末ペプチド医薬
KR20180041749A (ko) 2015-08-25 2018-04-24 바-일란 유니버시티 비대칭형 전기 화학 전지 장치 및 그 작동 방법
EP3624885A4 (en) 2017-05-19 2021-03-10 Trudell Medical International EXPIRATORY OVERPRESSURE DEVICE
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud
WO2021087037A1 (en) * 2019-10-29 2021-05-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Lung-specific targeting-peptide (ltp), compositions, and uses thereof
EP4051307B1 (en) 2020-05-08 2023-02-01 APEPTICO Forschung und Entwicklung GmbH Peptide for prevention or treatment of covid-19

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
CA2155103A1 (en) 1993-02-03 1994-08-18 Rudolph Lucas Tnf-alpha muteins and a process for preparing them
NZ509604A (en) 1998-08-14 2003-05-30 Innogenetics N TNF-derived peptides for use in treating oedema
EP1781323B1 (en) 2004-08-06 2010-02-17 Nycomed GmbH Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
CA2791847C (en) * 2009-03-04 2017-05-02 Mannkind Corporation An improved dry powder drug delivery system
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase

Also Published As

Publication number Publication date
EP2866824A1 (de) 2015-05-06
ES2602197T3 (es) 2017-02-20
AU2013283563A1 (en) 2015-01-15
EP2679239A1 (de) 2014-01-01
CA2875749A1 (en) 2014-01-03
KR102010793B1 (ko) 2019-08-14
CA2875749C (en) 2019-02-26
KR20150037815A (ko) 2015-04-08
PE20150198A1 (es) 2015-02-19
AP2014008162A0 (en) 2014-12-31
JP2015526399A (ja) 2015-09-10
CN104427993A (zh) 2015-03-18
CN104427993B (zh) 2017-03-08
AU2013283563B2 (en) 2017-06-08
EA201500061A1 (ru) 2015-06-30
WO2014001177A1 (de) 2014-01-03
EA030384B1 (ru) 2018-07-31
MX2014015048A (es) 2015-06-05
US20150225460A1 (en) 2015-08-13
EP2866824B1 (de) 2016-08-10
IN2015DN00585A (OSRAM) 2015-06-26
MX354302B (es) 2018-02-23
US9802985B2 (en) 2017-10-31
US20190211061A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
JP6113277B2 (ja) 酸素欠乏および気圧低下を原因とする高山病肺型の治療のための医薬組成物
CA2662716C (en) Method of treating respiratory disorders
AU2019240693B2 (en) Kv1.3 potassium channel antagonists
CA2708134C (en) Cyclic protein free from cysteines
KR102268955B1 (ko) 항분비 인자 17
US20020128203A1 (en) Methods of identifying inhibitory compounds and uses thereof
US20240325496A1 (en) Cxc chemokine agonists and antagonists in covid-19 disease and diagnostic assays
US9109041B2 (en) Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification
US20240002437A1 (en) Compositions and methods of treating inflammatory lung diseases
US8372799B2 (en) Reverse protein
US20190092814A1 (en) Peptide
Kovacs et al. Inhibition of long myosin light-chain kinase activation
BRPI0502399B1 (pt) Compostos análogos a peptídeos analgésicos derivados de veneno de serpentes crotalus durissus terrificus, seus usos, composições, métodos de preparação e de puruficação
HK1235416A1 (en) Kv1.3 potassium channel antagonists
HK1235416B (en) Kv1.3 potassium channel antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160422

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20160511

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20160601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170314

R150 Certificate of patent or registration of utility model

Ref document number: 6113277

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250